To view this email as a web page, click here.
Conference Coverage
 
 September 14, 2018
 
EADV 2018 is taking place this week in Paris. Here’s the latest from the meeting. Visit our conference page for more news from the meeting.
 
Advent of immunotherapy may require a new, expanded role for dermatologists
With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.
 
EADV report highlights the future of checkpoint inhibitors in advanced melanoma
Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.
 
EADV report shows that ixekizumab effectively treats nail psoriasis
Patients who undergo treatment with ixekizumab experience greater nail psoriasis improvement than individuals treated with ustekinumab.
 
EADV report shows that risankizumab is a consistent performer in psoriasis
Risankizumab performed better in treating psoriasis that appears on the nails, hands and feet, palms and scalp sores.
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.